Responders to renal cell carcinoma agent show longer survival rates

October 1, 2012

Responders to the multi-targeted receptor tyrosine kinase inhibitor sunitinib (Sutent) have significantly longer progression-free survival and overall survival than non-responders, according to an analysis of 1,059 patients who participated in six clinical trials of sunitinib as first- or second-line therapy of metastatic renal cell carcinoma.